Tech Company Financing Transactions

Chiasma Funding Round

Abingworth, MPM Capital and 7 Med Health Ventures participated in a $38.5 million Series D capital raise for Chiasma. The financing round was announced by the company on 7/24/2012.

Transaction Overview

Company Name
Chiasma
Announced On
7/24/2012
Transaction Type
Venture Equity
Amount
$38,500,000
Round
Series D
Investors

Abingworth (Lead Investor) (Vincent Miles)

MPM Capital (Lead Investor) (Todd Foley)

7 Med Health Ventures (Dror Brandwein)

Arch Venture Partners (Scott Minick)

F3 Ventures

Proceeds Purpose
The new investment (the D round) is expected to provide funding for the completion of the Phase 3 pivotal program in acromegaly patients for Octreolin (pronounced Ock-tree-o-lin), the Company's proprietary investigational oral form of the peptide octreotide, which is planned to be completed in the second quarter of 2013. It is also intended to finance a clinical study for the Company's second product, a small molecule to be investigated as a possible treatment for a complication of chronic kidney disease (CKD).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
460 Totten Pond Rd. 530
Waltham, MA 02451
USA
Phone
(866) 637-9703
Website
www.chiasmapharma.com
Email Address
[email protected]
Overview
Chiasma is focused on improving the lives of patients by developing and ultimately commercializing oral therapies that eliminate the significant limitations and burdens generally associated with therapies that are currently only available as injections.
Profile
Chiasma LinkedIn Company Profile
Social Media
Chiasma Company Twitter Account
Company News
Chiasma News
Facebook
Chiasma on Facebook
YouTube
Chiasma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Raj Kannan
  Raj Kannan LinkedIn Profile  Raj Kannan Twitter Account  Raj Kannan News  Raj Kannan on Facebook
Chief Medical Officer
William Ludlam
  William Ludlam LinkedIn Profile  William Ludlam Twitter Account  William Ludlam News  William Ludlam on Facebook
President
Mark Fitzpatrick
  Mark Fitzpatrick LinkedIn Profile  Mark Fitzpatrick Twitter Account  Mark Fitzpatrick News  Mark Fitzpatrick on Facebook
VP - Client Services
Asi Haviv
  Asi Haviv LinkedIn Profile  Asi Haviv Twitter Account  Asi Haviv News  Asi Haviv on Facebook
VP - Finance
Drew Enamait
  Drew Enamait LinkedIn Profile  Drew Enamait Twitter Account  Drew Enamait News  Drew Enamait on Facebook
VP - Marketing
Dana Gelbaum
  Dana Gelbaum LinkedIn Profile  Dana Gelbaum Twitter Account  Dana Gelbaum News  Dana Gelbaum on Facebook
VP - Regulatory Affairs
Shoshie Katz
  Shoshie Katz LinkedIn Profile  Shoshie Katz Twitter Account  Shoshie Katz News  Shoshie Katz on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/24/2012: Apigee venture capital transaction
Next: 7/25/2012: Alarm.com venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.